113211-15-7

Basic information

• Product Name: 2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE
• Synonyms: 2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE;N-(CYCLOPROPYL METHOXY)PHTHALIMIDE;2-CyclopropylMethoxyisoindole-1,3-dione;2-(CyclopropylMethoxy)isoindoline-1,3-dione
• CAS NO: 113211-15-7
• Molecular Formula: C₁₂H₁₁NO₃
• Molecular Weight: 217.22
• Product Categories: Aromatics Compounds;Aromatics;Heterocycles;Intermediates
• Mol File: 113211-15-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 71-77 °C
• Boiling Point: 350.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Solubility: Dimethyl Sulfoxide, Methanol
• CAS DataBase Reference: 2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE(113211-15-7)
• EPA Substance Registry System: 2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE(113211-15-7)

Safety Data

• Hazardous Substances Data: 113211-15-7(Hazardous Substances Data)

Usage

Description

2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE is a pale-yellow solid with chemical properties that make it a valuable compound in the pharmaceutical industry. It is primarily known for its role in the preparation of phenylaminobenzimidazoles and their analogs, which serve as MEK inhibitors.

Uses

Used in Pharmaceutical Industry:
2-(CYCLOPROPYLMETHOXY)-1H-ISOINDOLE-1,3(2H)-DIONE is used as a key intermediate compound for the synthesis of phenylaminobenzimidazoles and their analogs. These compounds act as MEK inhibitors, which are crucial in the treatment of chronic pain. By inhibiting MEK, a protein kinase involved in the regulation of cell growth and survival, these compounds can help alleviate pain and improve the quality of life for patients suffering from chronic pain conditions.
Additionally, the compound may have potential applications in other areas of the pharmaceutical industry, such as the development of new drugs targeting various diseases and disorders. However, further research and development are necessary to explore these possibilities fully.

Upstream product

• 524-38-9 N-hydroxyphthalimide 
• 2516-33-8 Cyclopropylmethanol 
• 7051-34-5 cyclopropylcarbinyl bromide 

Downstream Products

• 75647-90-4 O-cyclopropylmethyl-hydroxylamine 

Relevant articles and documents

Ligand-Enabled β-Methylene C(sp3)?H Arylation of Masked Aliphatic Alcohols

Despite recent advances, reactivity and site-selectivity remain significant obstacles for the practical application of C(sp3)?H bond functionalization methods. Here, we describe a system that combines a salicylic-aldehyde-derived L,X-type directing group with an electron-deficient 2-pyridone ligand to enable the β-methylene C(sp3)?H arylation of aliphatic alcohols, which has not been possible previously. Notably, this protocol is compatible with heterocycles embedded in both alcohol substrates and aryl coupling partners. A site- and stereo-specific annulation of dihydrocholesterol and the synthesis of a key intermediate of englitazone illustrate the practicality of this method.

HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS

The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tauntomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans

NOVEL COMPOUNDS AS RESPIRATORY STIMULANTS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention, The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.